Dietary Fat, Plasma Lipids, and Other CHD Risk Factors

Study Overview
=================
Brief Summary
-----------------
To assess the extent to which consumption of different sources of hydrogenated fat relative to unhydrogenated oil or butter alters plasma lipoprotein concentrations and measures of lipid metabolism.

Detailed Description
-----------------
BACKGROUND: Although the consumption of trans-fatty acids or hydrogenated fat has consistently been shown to elevate concentrations of total and LDL cholesterol, the effects on HDL-c and Lp(a) are inconsistent, especially when the fats were consumed at moderate levels. In addition, little is known about the mechanisms by which trans-fatty acids increase total and LDL cholesterol levels or how they may alter the atherogenecity of lipoprotein subfractions. The study interventions employ commonly used hydrogenated fats with a wide range of trans-fatty acid levels (1.5-9.8 percent). The impact will be assessed within the guidelines currently recommended for individuals with moderately elevated plasma levels for which dietary modification is often the first approach to treatment. The results of the study may lead to improved public health recommendations concerning trans-fatty acid and hydrogenated fat intake. DESIGN NARRATIVE: Forty subjects (20 male, 20 female) ages 50 or older, with LDL cholesterol concentrations greater than 130 mg/dl were fed each of five diets for eight week periods. The baseline diet consisted of 36 percent of energy as fat (15 percent saturated, 15 percent monosaturated, 6 percent polyunsaturated) and 160 mg cholesterol/1000 kcal. The experimental diets contained 30 percent energy as fat, 2/3 of which was derived from each of the following: 1) unhydrogenated liquid soybean oil, 2) soybean oil margarine in tub form, 3) commercial shortening, and 4) butter in a randomized double blind, cross-over design. With the exception of the experimental fat, all other foods in the reduced fat diets were identical. The study assessed the impact of consuming diets enriched in hydrogenated and other fats on a) plasma lipids and lipoprotein concentrations, b) apolipoproteins A-1 and B and Lp(a) concentrations, c) parameters related to HDL cholesterol [particle size, composition, subfraction distribution (HDL2 and HDL3, and HDL with and without A-II)], d) susceptibility of LDL to oxidation, e) activities of lecithin cholesterol acyltransferase (LCAT) and cholesterol ester transfer protein, and f) rates of endogenous cholesterol synthesis. The study was renewed in FY 2000 is to assess the impact of newer approaches to dietary modification with the intent of reducing the risk of developing cardiovascular disease. The specific aims of the study are as follow: 1) to assess the impact of substituting two classes of fats specifically formulated to substitute for hydrogenated fats (i.e., trans-free margarines and genetically modified/selectively bred oils) on serum lipid levels (total, VLDL, LDL, HDL, HDL2 and HDL3 cholesterol; triglyceride; apo A-l and B; Lp[a]), immune function, and prostaglandin levels, and 2) to address unresolved issues related to plant sterols, including the relative efficacy of currently available preparations, impact of the fat and cholesterol content of the diet, and effect of dosing frequency on serum lipids, endogenous cholesterol synthesis, cholesterol absorption, and fat soluble vitamin levels. Study subjects are older (50-75 y) hypercholesterolemic female and male subjects (LDL cholesterol 130-160 mg/dl). Each 5-week diet phase will be scheduled in randomized order; all food and drink will be provided. In Part 1, Study 1, subjects will consume each of 3 diets (30 percent fat [2/3 experimental fat], 80 mg cholesterol/1000 kcal) with the following experimental fats: conventional soft margarine; trans-free margarine (interesterified palm kernel + liquid oil); trans-free margarine (fully hydrogenated soybean oil + liquid oil). In Part 1, Study 2, subjects will consume each of 6 diets (as above) with the following experimental fats: hydrogenated soybean (shortening), high oleic sunflower, high oleic soybean, high oleic canola, low saturated soybean and low linolenic soybean oils. In Part 2, Study 1, subjects will consume each of 4 diets (38 percent fat [15 percent SFA, 14 percent MUFA, 6 percent PUFA], 200 mg cholesterol/1000 kcal), baseline and the following: sitostanol ester; sitostenol ester, and genetically modified high sterol oil. In Part 2, Study 2, subjects will consume each of 4 plant sterol enriched diets, high fat (as above) with high (200 mg) or low (80 mg) cholesterol/1000 kcal, and low fat (20 percent fat [5 percent SFA, 7.5 percent MUFA, 7.5 percent PUFA]) with high or low cholesterol. In Part 2, Study 3, the effect of dosing regime will be assessed using the most efficacious plant sterol as identified in Study 1 and diet as in Study 2 (single bolus or in 3 divided doses).

Conditions
-----------------
Atherosclerosis, Cardiovascular Diseases, Coronary Disease, Heart Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |